Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 197-199

  Duval, Xavier ^a   Descamps, Diane ^a   Breton, Guillaume ^a   Darmon, Sophie ^a   Ecobichon, Jean Luc ^a   Delarue, Séverine ^a   Peytavin, Gilles ^a   Leport, Catherine ^a   Vildé, Jean Louis ^a   Brun Vézinet, Françoise ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIREMIA; VIRUS LOAD; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; MUTATION; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIREMIA;

EID: 18344386680     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Abgrall S, Duval X, Joly V, Descamps D, Matheron S & Costagliola D. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clinical Infectious Diseases 2003; 37:1517-1526.
2. Deeks SG. Durable HIV treatment benefit despite low-level viremia - reassessing definitions of success or failure. Journal of the American Medical Association 2001; 286:224-226.
3. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G & Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16:1039-1044.
4. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF & Deeks SG. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18:981-989.
5. Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J Jr, Moore RD, Gallant JE, Persaud D & Siliciano RE Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clinical Infectious Diseases 2004; 39:1030-1037.